Clin2
NCT06321250Possibly a fitRecruiting

Study of a new tablet for advanced kidney cancer

Renal Cell Carcinoma Metastatic

Part of Cancer clinical trials.

This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
80 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have a type of kidney cancer called clear cell renal cell carcinoma that has spread to nearby tissues or other parts of the body.
  • You must have at least one tumor that can be measured on a scan (like a CT or MRI).
  • You must not have active brain metastases or cancer that has spread to the lining of the brain.
  • You must not have received certain cancer treatments (like chemotherapy, targeted therapy, or other study drugs) in the last 2 to 4 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07208136Recruiting· Phase 1
A study of JMKX005425 for certain advanced solid tumors

This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.

Beijing
NCT07239596Recruiting· Phase 1/Phase 2
Study of three drugs for advanced kidney cancer

This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.

Beijing, Beijing Municipality
NCT06800651Recruiting· Phase 2
A new drug for fast-growing polycystic kidney disease

This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.

Beijing, Beijing Municipality
NCT07253116Recruiting· Phase 1/Phase 2
Study of WJ22096 tablets for advanced solid tumors

This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.

Beijing, Beijing Municipality
NCT07227415Recruiting· Phase 1/Phase 2
Study of a new drug for advanced kidney cancer

This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.

Phoenix, Arizona
NCT06364631Recruiting· Phase 3
Testing a new approach for advanced kidney cancer

This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.

Vienna

Hear when a new Renal Cell Carcinoma Metastatic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.